^
    1year
    WT1 and PRAME RNA-loaded dendritic cell vaccine as maintenance therapy in de novo AML after intensive induction chemotherapy. (PubMed, Leukemia)
    Oral azacytidine may be used as maintenance treatment in AML in first remission, but can be associated with substantial side effects, and less toxic strategies should be explored. OS at five years was 75% (95% CI: 50-89), with 70% of patients ≥60 years of age being long-term survivors. Maintenance therapy with this DC vaccine was well tolerated in AML patients in CR1 and was accompanied by encouraging 5-year long-term survival.
    Journal
    |
    PRAME (Preferentially Expressed Antigen In Melanoma)
    |
    azacitidine • CVT-DC-01 • DC vaccine for prostate cancer
    over4years
    DC Vaccination for Post-remission Therapy in AML (clinicaltrials.gov)
    P1/2, N=20, Completed, Medigene AG | Active, not recruiting --> Completed | Trial completion date: Dec 2020 --> Nov 2019
    Clinical • Trial completion • Trial completion date
    |
    WT1 (WT1 Transcription Factor) • PRAME (Preferentially Expressed Antigen In Melanoma)
    |
    CVT-DC-01